0001209191-19-053665.txt : 20191018
0001209191-19-053665.hdr.sgml : 20191018
20191018195628
ACCESSION NUMBER: 0001209191-19-053665
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191016
FILED AS OF DATE: 20191018
DATE AS OF CHANGE: 20191018
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: NELSEN ROBERT
CENTRAL INDEX KEY: 0001219042
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39083
FILM NUMBER: 191158628
MAIL ADDRESS:
STREET 1: 8755 W. HIGGINS ROAD
STREET 2: SUITE 1025
CITY: CHICAGO
STATE: IL
ZIP: 60631
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vir Biotechnology, Inc.
CENTRAL INDEX KEY: 0001706431
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 812730369
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 499 ILLINOIS STREET
STREET 2: SUITE 500
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-906-4324
MAIL ADDRESS:
STREET 1: 499 ILLINOIS STREET
STREET 2: SUITE 500
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-10-16
0
0001706431
Vir Biotechnology, Inc.
VIR
0001219042
NELSEN ROBERT
8755 W. HIGGINS ROAD, SUITE 1025
CHICAGO
IL
60631
1
0
1
0
Common Stock
2019-10-16
4
C
0
11666665
A
12111109
I
See footnote
Common Stock
2019-10-16
4
C
0
15555554
A
15555554
I
See footnote
Common Stock
2019-10-16
4
P
0
1000000
20.00
A
1000000
I
See footnote
Series A-1 Convertible Preferred Stock
2019-10-16
4
C
0
11111110
D
Common Stock
11111110
0
I
See Footnote
Series A-1 Convertible Preferred Stock
2019-10-16
4
C
0
13333332
D
Common Stock
13333332
0
I
See Footnote
Series B Convertible Preferred Stock
2019-10-16
4
C
0
555555
D
Common Stock
555555
0
I
See Footnote
Series B Convertible Preferred Stock
2019-10-16
4
C
0
2222222
D
Common Stock
2222222
0
I
See Footnote
Each share of the Issuer's Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
The shares are held by ARCH Venture Fund IX, L.P. ("ARCH IX"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX, L.P., which is the sole general partner of ARCH IX, and shares voting and investment control with respect to shares held by ARCH IX. The Reporting Person may be deemed to beneficially own the shares held by ARCH IX, and the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, which is the sole general partner of ARCH Venture Partners IX Overage, L.P., the sole general partner of ARCH Overage, and shares voting and investment control with respect to shares held by ARCH Overage. The Reporting Person may be deemed to beneficially own the shares held by ARCH Overage, and the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These shares are directly held by GPLLC. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by GPLLC. Each of the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Each of ARCH IX and ARCH Overage has a pecuniary interest in the shares held by GPLLC.
/s/ Howard Horn, Attorney-in-Fact
2019-10-18